Hermetica Superfood Encyclopedia
The Short Answer
Icariin is a prenylated flavonoid glycoside derived from Epimedium (horny goat weed) that acts primarily as a phosphodiesterase type 5 (PDE5) inhibitor, increasing cyclic GMP levels to promote vasodilation and endothelial function. It also modulates estrogen receptors, Wnt/β-catenin signaling, and SIRT1 pathways, producing antioxidant, bone-protective, and cardioprotective effects documented extensively in preclinical models.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordicariin benefits
Synergy Pairings3
Icariin (3-(5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy-7-(β-D-glucopyranosyloxy)chromen-4-one) — botanical close-up
Health Benefits
Origin & History
Natural habitat
Icariin is a prenylated flavonol glycoside isolated primarily from plants in the genus Epimedium (Berberidaceae family), commonly known as horny goat weed or Yin Yang Huo. These perennial herbs grow on cliffs and wet lands at elevations of 200-3700 m from Japan to Algeria, and icariin is extracted from the herb tops or leaves for use in traditional Chinese medicine formulations.
“In traditional Chinese medicine, icariin-rich Epimedium (Ying Yang Huo or Herba Epimedii) has been used for over 1,000 years to treat coronary heart disease, impotence, osteoporosis, rheumatism, and as an aphrodisiac. Historical applications also include anti-aging and reproductive support.”Traditional Medicine
Scientific Research
Current evidence for icariin is limited to preclinical studies, with no human clinical trials, RCTs, or meta-analyses identified in the research. Animal models demonstrate cardiovascular benefits including lipid modulation and anti-atherosclerotic effects, while in vitro studies support antioxidant and anti-inflammatory mechanisms.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges for human use are available from the current research. Icariin is typically consumed as part of Epimedium extracts, but specific standardization percentages or therapeutic doses have not been established in human studies. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "carbohydrates": "Not applicable", "fats": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"icariin": "Primary bioactive compound", "concentration": "Varies depending on the source, typically found in concentrations ranging from 0.1% to 5% in Epimedium extracts"}, "bioavailability_notes": "Icariin's bioavailability is generally low due to poor water solubility and rapid metabolism. It may be enhanced through formulation strategies such as nanoparticle delivery systems."}
How It Works
Mechanism of Action
Icariin inhibits phosphodiesterase type 5 (PDE5), preventing the degradation of cyclic guanosine monophosphate (cGMP), which relaxes vascular smooth muscle and improves endothelial nitric oxide (NO) bioavailability. It activates the Wnt/β-catenin signaling pathway and upregulates RUNX2 and OPG expression to promote osteoblastogenesis while suppressing RANKL-driven osteoclast activity. Additionally, icariin scavenges reactive oxygen species (ROS), upregulates Nrf2-mediated antioxidant enzymes including superoxide dismutase (SOD) and catalase, and modulates ERα/ERβ estrogen receptor subtypes to exert phytoestrogenic effects.
Clinical Evidence
The majority of icariin research consists of in vitro cell studies and rodent models, with very limited randomized controlled trials in humans. Animal studies using doses of 10–100 mg/kg/day have demonstrated reductions in LDL-cholesterol, increases in HDL-cholesterol, and improved bone mineral density in ovariectomized mouse models of osteoporosis. A small number of Chinese clinical trials involving postmenopausal women (n=60–120) reported modest improvements in bone turnover markers and lipid profiles, though methodological quality and trial registration vary considerably. Evidence for erectile function improvement in humans remains largely anecdotal or derived from small, poorly controlled studies, and no large-scale Phase III trials have confirmed efficacy or optimal dosing in any indication.
Safety & Interactions
Icariin is generally considered well-tolerated at typical supplemental doses (150–1000 mg/day of standardized Epimedium extract), but high doses may cause dry mouth, dizziness, nosebleed, or rapid heartbeat in sensitive individuals. Due to its PDE5-inhibitory activity, icariin may potentiate the hypotensive effects of nitrate medications and PDE5 inhibitor drugs such as sildenafil (Viagra), and concurrent use is contraindicated. Its phytoestrogenic activity raises theoretical concerns for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine cancer, or endometriosis, and it should be avoided during pregnancy and lactation due to insufficient safety data. Icariin may also interact with CYP3A4-metabolized drugs by moderately inhibiting this hepatic enzyme, potentially altering plasma concentrations of affected medications.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
IcariinICAPrenylated flavonol glycosideHorny goat weed extractEpimedium extractYin Yang Huo active compoundYing Yang Huo glycosideHerba Epimedii flavonoidBarrenwort extractBishop's hat compoundFairy wings extract
Frequently Asked Questions
How does icariin compare to Viagra for erectile dysfunction?
Icariin inhibits PDE5 similarly to sildenafil (Viagra) but with significantly lower potency; its IC50 for PDE5 inhibition is approximately 0.43 µM compared to sildenafil's ~3.7 nM, making sildenafil roughly 100-fold more potent. Human clinical evidence for icariin's efficacy in erectile dysfunction is largely absent, with supporting data limited to rodent models showing improved corpus cavernosum smooth muscle relaxation. Combining icariin supplements with prescription PDE5 inhibitors is potentially dangerous due to additive hypotensive effects.
What is the recommended dosage of icariin for bone health?
No standardized human clinical dose for icariin has been established, but Chinese clinical trials examining bone health in postmenopausal women have used Epimedium extracts standardized to deliver approximately 60–200 mg of icariin per day. Animal osteoporosis studies demonstrating increased bone mineral density and osteoblast activity typically used 10–50 mg/kg/day, which does not translate directly to human dosing. Most commercial supplements provide 150–500 mg of Epimedium extract standardized to 10–40% icariin, but consumers should note these doses are not validated by large-scale human trials.
Does icariin act like estrogen in the body?
Yes, icariin exhibits phytoestrogenic activity by binding to both ERα and ERβ estrogen receptor subtypes, with a reported preference for ERβ, which is more prevalent in bone, the cardiovascular system, and the brain. This binding is considerably weaker than endogenous 17β-estradiol, placing icariin in the same category as other flavonoid phytoestrogens like genistein. Because of this activity, individuals with hormone-sensitive cancers, endometriosis, or uterine fibroids should consult a physician before using icariin-containing supplements.
Can icariin reduce cholesterol levels?
In animal models, oral icariin administration at 20–100 mg/kg/day has been shown to reduce total cholesterol and LDL-cholesterol by approximately 20–35% while increasing HDL-cholesterol, partly through upregulation of hepatic LDL receptor expression and inhibition of HMG-CoA reductase activity. These anti-atherosclerotic effects have been observed in ApoE-knockout mice fed high-fat diets, but no well-controlled human clinical trials have confirmed equivalent lipid-lowering effects in people. Therefore, icariin should not be used as a substitute for evidence-based lipid-lowering therapies such as statins.
Is icariin safe to take long-term?
Long-term human safety data for icariin is scarce, as most studies are short-term (8–24 weeks) and conducted in small populations, predominantly in China. Rodent toxicology studies have not identified significant organ toxicity at doses equivalent to typical human supplemental intake, but chronic high-dose consumption raises concerns about hormonal disruption due to phytoestrogenic activity and potential CYP3A4 enzyme inhibition affecting drug metabolism. Anyone taking prescription medications, particularly anticoagulants, cardiovascular drugs, or hormonal therapies, should consult a healthcare provider before sustained icariin use.
Does icariin interact with blood pressure medications or heart drugs?
Icariin may potentiate the effects of PDE5 inhibitors (like sildenafil) and blood pressure-lowering medications due to its vasodilatory mechanism, potentially causing excessive hypotension. While animal studies show cardiovascular benefits, human data on interactions with antihypertensive or cardiac medications is limited. Consult a healthcare provider before combining icariin with heart medications or antihypertensives.
What is the difference between icariin derived from Epimedium versus synthetic icariin?
Epimedium-derived icariin is extracted from the plant source and typically contains co-occurring flavonoids and bioactive compounds that may have synergistic effects, while synthetic icariin is a purified isolated compound. Most human studies and traditional use involve plant-derived extracts rather than isolated synthetic icariin. The bioavailability and efficacy of plant extracts versus pure icariin have not been directly compared in clinical trials.
How strong is the clinical evidence supporting icariin's cardiovascular and bone health benefits?
Most evidence for icariin's cardiovascular protection and bone health benefits comes from animal studies and in vitro research; robust human clinical trials are limited. The anti-atherosclerosis and antioxidant effects demonstrated in rodent models have not been conclusively replicated in large-scale randomized controlled trials in humans. Current clinical evidence is promising but insufficient to support strong medical claims without additional human research.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w icariin-4-oxo-4h-chromen-7-yl-oxy-7-chromen-4-one curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
